Abstract
Relebactam is a novel class A/C -lactamase inhibitor that restores imipenem in vitro activity against multidrug-resistant and carbapenem-nonsusceptible Pseudomonas aeruginosa. Time-kill analyses were performed to evaluate the potential role of imipenem-relebactam in combination with amikacin or colistin against P. aeruginosa. Ten clinical P. aeruginosa isolates (9 imipenem nonsusceptible) with imipenem-relebactam MICs ranging from 1/4 to 8/4 g/ml were included. The isolates had varied susceptibilities to imipenem (1 to 32 g/ml), amikacin (4 to 128 g/ml), and colistin (0.5 to 1 g/ml). Duplicate 24-h time-kill studies were conducted using the average steady-state concentrations (Cssavg) observed after the administration of imipenem-relebactam at 500 mg/250 mg every 6 hours (q6h) alone and in combination with the Cssavg of 25 mg/kg of body weight/day amikacin and 360 mg/day colistin in humans. Imipenem-relebactam alone resulted in 24-h bacterial densities of 2.93 0.38, 1.67 0.29, 0.38 0.96, and 0.15 0.65 log10 CFU/ml at imipenem-relebactam MICs of 1/4, 2/4, 4/4, and 8/4 g/ml, respectively. No synergy was demonstrated against the single imipenem-susceptible isolate. Against the imipenem-nonsusceptible isolates (n 9), imipenem-relebactam combined with amikacin resulted in synergy (2.61 1.50 log10 CFU/ml) against all amikacin-susceptible isolates and in two of three amikacin-intermediate (i.e., MIC, 32 g/ml) isolates (2.06 0.19 log10 CFU/ ml). Synergy with amikacin was not observed when the amikacin MIC was 32 g/ ml. Imipenem-relebactam combined with colistin demonstrated synergy in eight out of the nine imipenem-resistant isolates (3.17 1.00 log10 CFU/ml). Against these 10 P. aeruginosa isolates, imipenem-relebactam combined with either amikacin or colistin resulted in synergistic activity against the majority of strains. Further studies evaluating combination therapy with imipenem-relebactam are warranted.
Author supplied keywords
Cite
CITATION STYLE
Asempa, T. E., Nicolau, D. P., & Kuti, J. L. (2019). In vitro activity of imipenem-relebactam alone or in combination with amikacin or colistin against pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 63(9). https://doi.org/10.1128/AAC.00997-19
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.